Liste Actualités

All news

06 March 2013

Académie Vétérinaire de France

Nanotechnology in veterinary medicine

The French Veterinary Academy held the first conference on nanotechnology in veterinary medicine on 7 March 2013. The conference, organised by Bernard Charley at the INRA centre in Jouy-en-Josas, was an opportunity to present groundbreaking research on the subject, identify promising areas to pursue and discuss the foreseeable impact on veterinarian pharmacology and diagnostic capabilities.
“Tailor-made” antiviral compounds to fight influenza A

14 September 2023

By: INRA Press Service - Jacques Le Rouzic

“Tailor-made” antiviral compounds to fight influenza A

Scientists have identified on viral proteins the “nerve centres” which need to be targeted by therapeutic compounds in order to halt any proliferation that might cause influenza A. Using computer tools, it is possible to sketch the outlines of the antiviral compounds of tomorrow.
Service de néonatologie au CHU Hôtel-Dieu de Nantes, Hôpital Mère et Enfant. Les bébés prématurés y restent en couveuse jusqu'à la date théorique de leur naissance.
INRA and its partner DBV Technologies were just granted €600 000 by the French National Research Agency (ANR) to coordinate their know-how and develop an innovative and non-invasive vaccine against bronchiolitis. This subsidy launches a pre-clinical phase which will confirm the feasibility of a vaccine delivered via a skin patch for children under 2 years old.
photo de microscopie du virus influenza
In the frame of the Carnot Institute for Animal health “ICSA”, within the “Molecular Virology and Immunology” unit, INRA’s researchers steered by Dr Bernard Delmas have identified mutations within the Influenza A virus polymerase PA subunit that enable preparation of temperature-sensitive Influenza virus. They are now seeking industrial partners to transfer and develop this patented technology.
Research scientists in the Molecular Virology and Immunology Unit have developed a recombinant virus that procures partial protection against West Nile Virus in mice. This recombinant virus has proved to be a particularly interesting vector platform for the development of vaccines that can be used in animals and humans.

Join us